查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949489

CRISPR基因組療法市場－全球產業規模、佔有率、趨勢、機會及預測（依疾病類型、治療類型、給藥方式、最終用戶、標靶基因修飾、地區和競爭格局分類，2021-2031年）

Crispr Genomic Cure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Therapy Type, By Delivery Method, By End User, By Targeted Genetic Modification, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 CRISPR 基因組療法市場預計將從 2025 年的 36.9 億美元成長到 2031 年的 141.8 億美元，複合年成長率達到 25.15%。

該市場指的是利用叢集規律間隔短回文重複序列（CRISPR）技術，透過治療性介入對遺傳物質進行精確編輯，以治療癌症和嚴重先天性疾病。全球遺傳疾病盛行率的不斷上升以及關鍵監管核准批准基因編輯的臨床療效，是推動市場成長的主要因素，同時強大的研發管線也為其提供了有力支撐。根據美國基因與細胞治療學會（ASCT）統計，截至2024年第一季，全球有超過4000種基因、細胞和RNA療法正在研發中，凸顯了推動市場加速發展的龐大規模。

市場概覽
預測期 2027-2031
市場規模：2025年 36.9億美元
市場規模：2031年 141.8億美元
複合年成長率：2026-2031年 25.15%
成長最快的細分市場 遺傳性疾病
最大的市場 北美洲

然而，由於生產和治療成本高昂，這些療法的應用仍存在許多障礙，尤其是在醫保報銷方面。這些經濟障礙常常會延遲藥物上市，並限制已通過核准治療方法的商業性擴充性，尤其是在醫療預算有限的地區。因此，建立永續的定價模式仍然是一項重大挑戰，可能會阻礙這些療法的廣泛治療方法。

市場促進因素

First-in-Class基因編輯治療方法的商業性檢驗與上市是市場擴張的重要催化劑，標誌著CRISPR技術正從實驗科學走向實際治療應用。 Exagamgrogen Autotemcel（Casgevy）近期獲得監管部門核准並投入商業性應用，為臨床療效樹立了重要先例，有助於更廣泛的應用和基礎設施建設。製藥公司正積極建立一個專門的網路來管理這些複雜的治療方法。例如，Vertex Pharmaceuticals在其2024年11月發布的第三季財報中指出，截至10月中旬，該公司已在全球範圍內運作了45家經認證的治療中心，以支持其基於CRISPR治療方法的商業性化應用，這表明該行業致力於克服物流方面的挑戰。

另一個推動因素是創業投資和政府對基因組學研究的資助激增，這對於維持臨床開發和生產創新的高成本至關重要。儘管面臨更廣泛的經濟逆風，該領域仍持續吸引大量資金，使生技公司能夠推進其研發管線並改善遞送機制。根據再生醫學聯盟在2024年10月舉行的梅薩細胞與基因會議上的報告，2024年上半年全球對細胞和基因治療領域的投資達109億美元。這筆資金的湧入為新興企業公司和成熟公司都提供了支持。例如，CRISPR Therapeutics公司在其2024年11月發布的「2024年第三季財報」中表示，公司擁有約19億美元的現金和證券，財務狀況穩健，確保了其正在進行的臨床項目的持續資源供應。

市場挑戰

全球CRISPR基因組療法市場面臨許多挑戰，主要原因在於其生產和應用高成本。這類治療性介入通常需要複雜的個人化生產流程，對患者細胞進行改造後再重新導入體內，這需要專門的設施和嚴格的品管。這種複雜的供應鏈必然會增加營運成本，迫使製藥公司提高價格以彌補巨額研發投入。這導致保險公司和預算有限的國家醫療體系對其產生抵觸情緒。

這些高昂的定價結構造成了巨大的報銷壁壘，限制了病患的就醫途徑，並延緩了商業性推廣。支付方經常仔細審查這些資本密集、單劑量療法的價值，導致漫長的談判期和延遲報銷。據再生醫學聯盟稱，首個核准的基於 CRISPR 的治療方法在 2024 年的定價為每位患者 220 萬美元。如此沉重的經濟負擔阻礙了這些根治性治療方法的廣泛應用，尤其是在醫療資金有限的地區，直接抑制了整體市場擴張和收入潛力。

市場趨勢

向精準的先導基因編輯和鹼基編輯的轉變代表著市場的一次根本性變革。它超越了第一代Cas9酶產生的雙鏈斷裂，朝著更安全地修正點突變的方向發展。這一趨勢的特點是，業界對能夠解決複雜基因異常且無脫靶效應或染色體易位風險的技術信心日益增強，製藥公司也正透過策略性投資不斷驗證這些平台。在2024年9月發布的「策略重點研發管線公告」中，Prime Medicine宣布已與百時美施貴寶公司合作開發體外T細胞療法。該公司接受1.1億美元的預付款，用於進一步開發這項新一代基因編輯技術。

同時，體內遞送機制，特別是非病毒脂質奈米顆粒（LNP），正迅速發展，旨在規避體外細胞工程的物流流程。這些載體能夠直接系統性地遞送基因編輯裝置，顯著降低了目前自體療法的生產負擔和基礎設施需求。該領域的臨床進展表明，LNP包裹的CRISPR組件能夠實現顯著的治療效果。根據Intellia Therapeutics公司2024年10月發布的報告《NTLA-2002公佈II期研究的積極結果》，該公司的一項體內實驗性治療，單次50毫克劑量即可使平均每月癲癇發作率較安慰劑組降低81%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球CRISPR基因組療法市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、感染疾病、神經系統疾病、心血管疾病、血液疾病、代謝性疾病、其他）
    • 依治療方法（基因編輯、基因治療、細胞治療、免疫療法）
    • 依給藥途徑（體內給藥、體外給藥）
    • 依最終用戶（醫院/診所、研究機構、生技/製藥公司）分類
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美CRISPR基因組療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲 CRISPR 基因組療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區CRISPR基因組療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲 CRISPR 基因組療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲CRISPR基因組療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球CRISPR基因組療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck KGaA
  • Takara Bio Inc
  • Lonza Group AG
  • Horizon Discovery Group Ltd
  • Genscript Biotech Corp
  • Synthego Corp
  • Precision BioSciences Inc
  • Mammoth Biosciences Inc
  • Thermo Fisher Scientific Inc
  • Intellia Therapeutics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17664

The Global Crispr Genomic Cure Market is projected to expand from USD 3.69 Billion in 2025 to USD 14.18 Billion by 2031, achieving a Compound Annual Growth Rate (CAGR) of 25.15%. This market involves therapeutic interventions utilizing Clustered Regularly Interspaced Short Palindromic Repeats technology to precisely edit genetic material for the treatment of oncology indications and severe congenital disorders. The market's growth is driven by the increasing global prevalence of genetic diseases and significant regulatory approvals that have validated the clinical efficacy of gene editing, further supported by a robust industrial pipeline. According to the American Society of Gene & Cell Therapy, over 4,000 gene, cell, and RNA therapies were in development globally during the first quarter of 2024, highlighting the immense scale of activity propelling market acceleration.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.69 Billion
Market Size 2031USD 14.18 Billion
CAGR 2026-203125.15%
Fastest Growing SegmentGenetic Disorder
Largest MarketNorth America

However, the sector encounters a major obstacle due to the exorbitant costs linked to manufacturing and patient administration, which create substantial reimbursement hurdles. These financial barriers frequently delay market access and restrict the commercial scalability of approved therapies, especially in regions with limited healthcare budgets. Consequently, establishing sustainable pricing models remains the primary challenge that could hinder the widespread adoption of these curative treatments.

Market Driver

The commercial validation and launch of first-in-class gene editing treatments act as a primary catalyst for market expansion, signaling the transition of CRISPR technology from experimental science to viable therapeutic reality. The recent regulatory approvals and commercial rollout of exagamglogene autotemcel (Casgevy) have set a critical precedent for clinical efficacy, fostering wider adoption and infrastructure development. Pharmaceutical companies are aggressively building specialized networks to administer these complex therapies; for instance, Vertex Pharmaceuticals reported in its 'Third Quarter 2024 Financial Results' in November 2024 that it had activated 45 authorized treatment centers globally by mid-October to support the commercial administration of its CRISPR-based therapy, demonstrating the industry's commitment to overcoming logistical challenges.

A parallel driver is the surge in venture capital and government funding for genomic research, which is essential for sustaining the high costs of clinical development and manufacturing innovation. Despite broader economic headwinds, the sector continues to attract significant capital, enabling biotechnology firms to advance their pipelines and refine delivery mechanisms. According to the Alliance for Regenerative Medicine's October 2024 presentation at the 'Cell & Gene Meeting on the Mesa', global investment in the cell and gene therapy sector reached $10.9 billion in the first half of 2024. This financial influx supports both startups and established players; for example, CRISPR Therapeutics noted in its 'Third Quarter 2024 Financial Results' in November 2024 that it maintained a robust balance sheet with approximately $1.9 billion in cash and securities, ensuring sustained resources for its ongoing clinical programs.

Market Challenge

The Global CRISPR Genomic Cure Market faces a significant impediment due to the high costs associated with manufacturing and patient administration. These therapeutic interventions typically necessitate complex, individualized production processes where patient cells are modified and reintroduced, requiring specialized facilities and rigorous quality control. This intricate supply chain inherently raises operational expenditures, compelling pharmaceutical developers to set high market prices to recover their substantial research and development outlays, which creates friction with insurance providers and national health systems operating under finite budgets.

These elevated pricing structures result in severe reimbursement hurdles that restrict patient access and slow commercial adoption. Payers frequently scrutinize the value of such capital-intensive one-time treatments, leading to prolonged negotiation periods and coverage delays. According to the Alliance for Regenerative Medicine, the list price for the first approved CRISPR-based therapy was established at $2.2 million per patient in 2024. This distinct financial burden limits the widespread scalability of these curative options, particularly in regions with constrained healthcare funding, thereby directly hampering the overall expansion and revenue potential of the market.

Market Trends

The transition to high-precision prime and base editing represents a fundamental shift in the market, moving beyond the double-strand breaks induced by first-generation Cas9 enzymes to potentially safer corrections of point mutations. This trend is characterized by growing industrial confidence in these technologies to address complex genetic errors without the risks of off-target effects or chromosomal translocations, with pharmaceutical entities increasingly validating these platforms through strategic investments. According to Prime Medicine, in its September 2024 'Prime Medicine Unveils Strategically Focused Pipeline' announcement, the company entered a collaboration with Bristol Myers Squibb to develop ex vivo T-cell therapies, receiving an upfront consideration of $110 million to advance these next-generation editing capabilities.

Simultaneously, the market is experiencing rapid advancement in in vivo delivery mechanisms, particularly non-viral lipid nanoparticles (LNPs), which aim to circumvent the logistical complexities of ex vivo cell engineering. By enabling the direct systemic administration of gene editors, these vectors significantly reduce the manufacturing burden and infrastructure requirements associated with current autologous therapies. Clinical progress in this domain is demonstrating the capability of LNP-encapsulated CRISPR components to achieve potent therapeutic outcomes; according to Intellia Therapeutics' October 2024 report 'Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002', a single 50 mg dose of their in vivo investigational therapy resulted in a mean monthly attack rate reduction of 81% compared to placebo.

Key Market Players

  • Merck KGaA
  • Takara Bio Inc
  • Lonza Group AG
  • Horizon Discovery Group Ltd
  • Genscript Biotech Corp
  • Synthego Corp
  • Precision BioSciences Inc
  • Mammoth Biosciences Inc
  • Thermo Fisher Scientific Inc
  • Intellia Therapeutics Inc

Report Scope

In this report, the Global Crispr Genomic Cure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crispr Genomic Cure Market, By Disease Type

  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disorders
  • Blood Disorders
  • Metabolic Disorders
  • Others

Crispr Genomic Cure Market, By Therapy Type

  • Gene Editing
  • Gene Therapy
  • Cell Therapy
  • Immunotherapy

Crispr Genomic Cure Market, By Delivery Method

  • In vivo
  • Ex vivo

Crispr Genomic Cure Market, By End User

  • Hospitals & Clinics
  • Research Institutes
  • Biotechnology & Pharmaceutical Companies

Crispr Genomic Cure Market, By Targeted Genetic Modification

  • Single Gene Modification
  • Multiple Gene Modification
  • Genome-wide Modification

Crispr Genomic Cure Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crispr Genomic Cure Market.

Available Customizations:

Global Crispr Genomic Cure Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Crispr Genomic Cure Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 5.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 5.2.3. By Delivery Method (In vivo, Ex vivo)
    • 5.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 5.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Crispr Genomic Cure Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy Type
    • 6.2.3. By Delivery Method
    • 6.2.4. By End User
    • 6.2.5. By Targeted Genetic Modification
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Crispr Genomic Cure Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy Type
        • 6.3.1.2.3. By Delivery Method
        • 6.3.1.2.4. By End User
        • 6.3.1.2.5. By Targeted Genetic Modification
    • 6.3.2. Canada Crispr Genomic Cure Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy Type
        • 6.3.2.2.3. By Delivery Method
        • 6.3.2.2.4. By End User
        • 6.3.2.2.5. By Targeted Genetic Modification
    • 6.3.3. Mexico Crispr Genomic Cure Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy Type
        • 6.3.3.2.3. By Delivery Method
        • 6.3.3.2.4. By End User
        • 6.3.3.2.5. By Targeted Genetic Modification

7. Europe Crispr Genomic Cure Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy Type
    • 7.2.3. By Delivery Method
    • 7.2.4. By End User
    • 7.2.5. By Targeted Genetic Modification
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Crispr Genomic Cure Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy Type
        • 7.3.1.2.3. By Delivery Method
        • 7.3.1.2.4. By End User
        • 7.3.1.2.5. By Targeted Genetic Modification
    • 7.3.2. France Crispr Genomic Cure Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy Type
        • 7.3.2.2.3. By Delivery Method
        • 7.3.2.2.4. By End User
        • 7.3.2.2.5. By Targeted Genetic Modification
    • 7.3.3. United Kingdom Crispr Genomic Cure Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy Type
        • 7.3.3.2.3. By Delivery Method
        • 7.3.3.2.4. By End User
        • 7.3.3.2.5. By Targeted Genetic Modification
    • 7.3.4. Italy Crispr Genomic Cure Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy Type
        • 7.3.4.2.3. By Delivery Method
        • 7.3.4.2.4. By End User
        • 7.3.4.2.5. By Targeted Genetic Modification
    • 7.3.5. Spain Crispr Genomic Cure Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy Type
        • 7.3.5.2.3. By Delivery Method
        • 7.3.5.2.4. By End User
        • 7.3.5.2.5. By Targeted Genetic Modification

8. Asia Pacific Crispr Genomic Cure Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy Type
    • 8.2.3. By Delivery Method
    • 8.2.4. By End User
    • 8.2.5. By Targeted Genetic Modification
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Crispr Genomic Cure Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy Type
        • 8.3.1.2.3. By Delivery Method
        • 8.3.1.2.4. By End User
        • 8.3.1.2.5. By Targeted Genetic Modification
    • 8.3.2. India Crispr Genomic Cure Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy Type
        • 8.3.2.2.3. By Delivery Method
        • 8.3.2.2.4. By End User
        • 8.3.2.2.5. By Targeted Genetic Modification
    • 8.3.3. Japan Crispr Genomic Cure Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy Type
        • 8.3.3.2.3. By Delivery Method
        • 8.3.3.2.4. By End User
        • 8.3.3.2.5. By Targeted Genetic Modification
    • 8.3.4. South Korea Crispr Genomic Cure Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy Type
        • 8.3.4.2.3. By Delivery Method
        • 8.3.4.2.4. By End User
        • 8.3.4.2.5. By Targeted Genetic Modification
    • 8.3.5. Australia Crispr Genomic Cure Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy Type
        • 8.3.5.2.3. By Delivery Method
        • 8.3.5.2.4. By End User
        • 8.3.5.2.5. By Targeted Genetic Modification

9. Middle East & Africa Crispr Genomic Cure Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy Type
    • 9.2.3. By Delivery Method
    • 9.2.4. By End User
    • 9.2.5. By Targeted Genetic Modification
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Crispr Genomic Cure Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy Type
        • 9.3.1.2.3. By Delivery Method
        • 9.3.1.2.4. By End User
        • 9.3.1.2.5. By Targeted Genetic Modification
    • 9.3.2. UAE Crispr Genomic Cure Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy Type
        • 9.3.2.2.3. By Delivery Method
        • 9.3.2.2.4. By End User
        • 9.3.2.2.5. By Targeted Genetic Modification
    • 9.3.3. South Africa Crispr Genomic Cure Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy Type
        • 9.3.3.2.3. By Delivery Method
        • 9.3.3.2.4. By End User
        • 9.3.3.2.5. By Targeted Genetic Modification

10. South America Crispr Genomic Cure Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy Type
    • 10.2.3. By Delivery Method
    • 10.2.4. By End User
    • 10.2.5. By Targeted Genetic Modification
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Crispr Genomic Cure Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy Type
        • 10.3.1.2.3. By Delivery Method
        • 10.3.1.2.4. By End User
        • 10.3.1.2.5. By Targeted Genetic Modification
    • 10.3.2. Colombia Crispr Genomic Cure Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy Type
        • 10.3.2.2.3. By Delivery Method
        • 10.3.2.2.4. By End User
        • 10.3.2.2.5. By Targeted Genetic Modification
    • 10.3.3. Argentina Crispr Genomic Cure Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy Type
        • 10.3.3.2.3. By Delivery Method
        • 10.3.3.2.4. By End User
        • 10.3.3.2.5. By Targeted Genetic Modification

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Crispr Genomic Cure Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Takara Bio Inc
  • 15.3. Lonza Group AG
  • 15.4. Horizon Discovery Group Ltd
  • 15.5. Genscript Biotech Corp
  • 15.6. Synthego Corp
  • 15.7. Precision BioSciences Inc
  • 15.8. Mammoth Biosciences Inc
  • 15.9. Thermo Fisher Scientific Inc
  • 15.10. Intellia Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer